ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

2019-nCoV Vaccine mRNA-1273

Also written as “mRNA-1273”, “mRNA-1273.815” and “mRNA-1273.529”.

Its studies are mostly in COVID-19 · Coronavirus Infections · Papillomavirus Infections · Influenza, Human, led by 4 companies.

Drug page2019-nCoV Vaccine mRNA-1273: every studyAll 41 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 3, 202420 company-led studies, 3 open or runningNext primary completion: Dec 11, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moderna173 open or runningphase 4since Sep 3, 2024May 13, 2020Dec 11, 2026phase 4 · NCT07863635
Merckits history only10 open or runningphase 3since Nov 10, 2021Nov 10, 2021none ahead
Regeneron Pharmaceuticalsits history only10 open or runningphase 2since Apr 19, 2021Apr 19, 2021none ahead
Takedaits history only10 open or runningphase 2since Dec 18, 2020Dec 18, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Moderna only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since May 13, 2020.

  1. Mar 11, 2021Phase 3 study in Coronavirus InfectionsNCT04796896 · 11,942 enrolled · United States, Canada
  2. Mar 22, 2021Phase 1 study in Coronavirus InfectionsNCT04813796 · 104 enrolled · United States
  3. Apr 21, 2021Phase 3 study in Coronavirus InfectionsNCT04860297 · 234 enrolled · United States
  4. Jun 14, 2021Phase 3 study in Coronavirus InfectionsNCT04927065 · 5,161 enrolled · United States
  5. Feb 19, 2022Phase 3 study in Coronavirus InfectionsNCT05249829 · 3,548 enrolled · United Kingdom
  6. May 13, 2022Phase 2 study in Influenza, HumanNCT05375838 · 550 enrolled · United States
  7. May 25, 2022Phase 1 study in Coronavirus InfectionsNCT05397223 · 308 enrolled · United States
  8. Jun 27, 2022Phase 3 study in COVID-19NCT05436834 · 1,807 enrolled · United States, Argentina, Chile and more
  9. Apr 13, 2023Phase 3 study in COVID-19NCT05815498 · 13,553 enrolled · United States, Canada, Japan and more
  10. Apr 5, 2024Phase 3 study in Coronavirus InfectionsNCT06354998 · 217 enrolled · Australia
  11. Sep 3, 2024Phase 4 study in Coronavirus InfectionsNCT06585241 · 1,144 planned · United States
  12. Oct 8, 2024Phase 4 study in Healthy VolunteersNCT06634797 · 1,000 enrolled · United States
  13. Nov 25, 2025Phase 4 study in Coronavirus InfectionsNCT07266558 · 30,000 enrolled · United States
  14. Oct 2, 2026Phase 4 study in Coronavirus InfectionsNCT07863635 · 600 planned · United States

Ahead

  1. Dec 11, 2026Primary completion: phase 4 study in Coronavirus InfectionsNCT07863635
  2. Dec 31, 2026Primary completion: phase 4 study in Coronavirus InfectionsNCT06585241
  3. Jun 16, 2027Primary completion: phase 4 study in Coronavirus InfectionsNCT07266558

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A vaccine consisting of a lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding the full-length, prefusion stabilized spike (S) protein of SARS-CoV-2, ”NCIt, by rule
“Spike glycoprotein vaccine antigen”ChEMBL 37, by rule

Studies

All 17 Moderna leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07863635Coronavirus Infections · United States4RecruitingDec 11, 2026600
NCT07266558Coronavirus Infections · United States4Active, not recruitingJun 16, 202730,000
NCT06634797Healthy Volunteers · United States4CompletedJan 20, 20251,000
NCT06585241Coronavirus Infections · United States4RecruitingDec 31, 20261,144
NCT06354998Coronavirus Infections · Australia3CompletedMay 10, 2024217
NCT05815498COVID-19 · United States, Canada, Japan and more3CompletedApr 12, 202513,553
NCT05436834COVID-19 · United States, Argentina, Chile and more3CompletedOct 20, 20251,807
NCT05397223Coronavirus Infections · United States1CompletedFeb 27, 2026308
NCT05375838Influenza, Human · United States2CompletedDec 29, 2022550
NCT05249829Coronavirus Infections · United Kingdom3CompletedJun 23, 20233,548
NCT04927065Coronavirus Infections · United States3CompletedNov 17, 20235,161
NCT04860297Coronavirus Infections · United States3CompletedMay 22, 2023234
NCT04813796Coronavirus Infections · United States1CompletedJul 25, 2023104
NCT04796896Coronavirus Infections · United States, Canada3CompletedMar 15, 202411,942
NCT04649151Coronavirus Infections · United States, Dominican Republic3CompletedJun 14, 20244,328
NCT04470427Coronavirus Infections · United States3CompletedDec 29, 202230,415
NCT04405076Coronavirus Infections · United States2CompletedOct 28, 2021660

How it is read

Names in the registry

  • “mRNA-1273”, 10 entries
  • “mRNA-1273.815”, 3 entries
  • “mRNA-1273.529”, 2 entries
  • “mRNA-1273 Variant-containing Formulation”, 1 entry
  • “mRNA-1273 Vaccine”, 1 entry

Codes read as this program: MRNA1273.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.